Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Novartis stares down $16.7B post-2030 patent cliff
Three of Novartis’ largest current growth pillars are projected to plunge from $23.9 billion in sales in 2030 to just $7.2 billion in 2035.
Angus Liu
Nov 19, 2026 11:45am
Arcera floats $1B+ total to license Innogen's GLP-1 beyond China
Nov 19, 2026 11:30am
AI’s Real Prize: Building Tomorrow’s CI Capability
Brought to you by
Eradigm
Regeneron breaks into gMG with FDA nod for siRNA med Livsayis
Nov 19, 2026 11:16am
Digital Twins: Advancing Clinical Evidence Strategy
Brought to you by
IQVIA
J&J draws FDA rebuke over Inlexzo bladder-sparing benefit claim
Nov 19, 2026 10:45am